Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Consensus Rating of “Moderate Buy” from Brokerages

Celldex Therapeutics, Inc. (NASDAQ:CLDX) has earned a consensus recommendation of “Moderate Buy” from the nine analysts that are covering the company, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation, six have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $62.25.

Several research analysts recently weighed in on the stock. HC Wainwright restated a “buy” rating and issued a $80.00 price objective on shares of Celldex Therapeutics in a research report on Thursday. Citigroup assumed coverage on shares of Celldex Therapeutics in a research report on Monday, October 7th. They issued a “buy” rating and a $70.00 price objective on the stock. Wolfe Research cut shares of Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a research report on Friday, September 27th. Cantor Fitzgerald restated an “overweight” rating and issued a $67.00 price objective on shares of Celldex Therapeutics in a research report on Monday, September 16th. Finally, Wells Fargo & Company raised Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Thursday, September 26th.

Celldex Therapeutics Stock Down 4.2 %

Shares of CLDX opened at $26.47 on Friday. The business’s 50-day moving average price is $33.90 and its 200-day moving average price is $35.90. Celldex Therapeutics has a twelve month low of $24.43 and a twelve month high of $53.18. The stock has a market cap of $1.75 billion, a PE ratio of -9.66 and a beta of 1.60.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.64) earnings per share for the quarter, beating the consensus estimate of ($0.69) by $0.05. The firm had revenue of $3.19 million for the quarter, compared to analysts’ expectations of $1.44 million. Celldex Therapeutics had a negative return on equity of 23.66% and a negative net margin of 1,809.18%. Analysts expect that Celldex Therapeutics will post -2.5 earnings per share for the current fiscal year.

Institutional Trading of Celldex Therapeutics

Institutional investors have recently made changes to their positions in the stock. Novo Holdings A S boosted its stake in shares of Celldex Therapeutics by 13.4% during the third quarter. Novo Holdings A S now owns 963,663 shares of the biopharmaceutical company’s stock valued at $32,755,000 after purchasing an additional 113,663 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in shares of Celldex Therapeutics by 631.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 3,087,208 shares of the biopharmaceutical company’s stock valued at $129,571,000 after purchasing an additional 2,664,915 shares during the period. Swiss National Bank boosted its stake in shares of Celldex Therapeutics by 17.8% during the first quarter. Swiss National Bank now owns 114,300 shares of the biopharmaceutical company’s stock valued at $4,797,000 after purchasing an additional 17,300 shares during the period. Bellevue Group AG boosted its stake in shares of Celldex Therapeutics by 15.7% during the first quarter. Bellevue Group AG now owns 2,796,615 shares of the biopharmaceutical company’s stock valued at $117,374,000 after purchasing an additional 380,319 shares during the period. Finally, AlphaCentric Advisors LLC boosted its stake in shares of Celldex Therapeutics by 23.4% during the second quarter. AlphaCentric Advisors LLC now owns 47,500 shares of the biopharmaceutical company’s stock valued at $1,758,000 after purchasing an additional 9,000 shares during the period.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.